Refine by
Respiratory Syncytial Articles & Analysis
20 news found
There are no approved or effective BKV treatments. Expanding into Respiratory Viruses A Phase 1/2 POC study of ALVR106, an investigational multi-respiratory VST therapy designed to target infections and diseases caused by human metapneumovirus, influenza, parainfluenza virus and respiratory syncytial virus in autologous and ...
ByKalaris
[i] Atriva specifically develops first-in-class, host-targeting small molecules that aim to inhibit viral replication and to favorably modulate the body’s immune response to treat severe respiratory diseases induced by RNA viruses. “Hantavirus infections and the resulting diseases, Hantavirus Pulmonary Syndrome and Hemorrhagic Fever with Renal Syndrome, are ...
Separately, the company also announced the initiation of a Phase 1/2 clinical trial (NCT04933968) of ALVR106, its investigational, allogeneic, off-the-shelf, multi-VST therapy for the treatment of infections caused by human metapneumovirus (hMPV), influenza, parainfluenza virus (PIV) and respiratory syncytial virus (RSV). This trial extends AlloVir’s VST ...
ByKalaris
The AscencioDx offers: Rapid test results equivalent to lab-based PCR tests Easy and comfortable lower nasal swab sampling procedure Positive test results in approximately 30 minutes Simple reporting process not requiring a complicated phone app or use of Bluetooth™ Price comparable to less accurate antigen tests and much lower than lab-based PCR tests Detector reusable for at least ...
Furthermore, the data show that MV-014-212 stimulates mucosal (nasal IgA) antibodies in the upper respiratory tract, the major infection route for SARS-CoV-2, and systemic (serum neutralizing and binding IgG) antibodies. ...
The data confirm the potential of V-306 for prophylaxis against Respiratory Syncytial Virus (RSV) infection, possibly using a convenient needle-free method of vaccination. ...
· No vaccine is currently approved to protect against respiratory syncytial virus (RSV) · RSV is the leading cause of infant hospitalization in the United States and is considered the “missing” pediatric vaccine · Previous clinical data in seropositive adult and pediatric participants showed MV-012-968 was well-tolerated, ...
While circulating antibodies are important for preventing serious lung disease, mucosal antibodies are important for blocking infection and transmission of respiratory viruses. “Compared to injected vaccines, intranasal vaccines have greater potential to stop the transmission of SARS-CoV-2,” said Martin Moore, Ph.D., CEO and Cofounder of Meissa. ...
Beyond COVID-19 testing, Mesa Biotech's existing platform includes tests for flu, respiratory syncytial virus (RSV), and Strep A. "The Accula System complements our existing offerings and immediately provides our clinical customers with more options and flexibility for COVID-19 testing. ...
- The randomized, double-blind, placebo-controlled challenge study is designed to evaluate safety and prophylactic efficacy of MV-012-968 against symptomatic respiratory syncytial virus (RSV) - Previous clinical data shows MV-012-968 is well-tolerated, heavily attenuated, and induces an RSV-specific mucosal IgA response in healthy seropositive adults and ...
Mesa Biotech has developed and commercialized a PCR-based rapid point-of-care testing platform available for detecting infectious diseases including SARS-CoV-2, Influenza A and B, respiratory syncytial virus (RSV) and Strep A. Mesa Biotech's patented technology expands the availability of gold standard nucleic acid PCR amplification to point-of-care diagnostics. ...
Thermo Fisher Scientific announces CE-marking of its TaqPath COVID-19, Flu A/B, RSV Combo Kit for the in vitro diagnosis of SARS-CoV-2, influenza A/B and respiratory syncytial virus (RSV) A/B infections. Using the new kit, laboratories can now can run a single test for SARS-CoV-2, influenza (flu) A/B, and RSV to detect and differentiate between diseases that ...
The new Vitassay SARS-CoV-2 + Flu A + B + RSV + Adeno Resp. is a rapid, immunochromatographic assay for the simultaneous qualitative detection of nucleoprotein antigen of SARS-CoV-2, Influenza type A, Influenza type B, RSV and Adenovirus from nasopharyngeal swabs samples from patients suspected of COVID-19 infection and/or Influenza A and/or Influenza B and/or Respiratory ...
Virometix, a privately held Swiss biotechnology company developing a new generation of vaccines and immunotherapeutic drugs for the prevention and treatment of infectious and oncology diseases, announced today the completion of initial vaccination of the first dose cohort in the Phase 1 healthy volunteer study of V-306, its candidate vaccine for prophylaxis of RSV (Respiratory ...
Meissa’s COVID-19 vaccine candidate, MV-014-210, is designed to be delivered as a single, intranasal, adjuvant-free dose, that is economical and can be rapidly scaled to supply global demands Preliminary clinical data show MV-012-968, the company’s vaccine candidate for respiratory syncytial virus, is heavily attenuated and induces a RSV-specific ...
Alveo Technologies, a leader in developing novel technologies that enable real-time, low-cost, at-home molecular detection of infectious disease, announced today that it has entered into a research collaboration with Janssen Pharmaceuticals, Inc., (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to advance Alveo’s be.well™ platform of analyzers, nasal ...
Virometix, a privately held Swiss biotechnology company developing a new generation of vaccines and immunotherapeutic drugs for the prevention and treatment of infectious and oncology diseases, is pleased to announce that the Belgian health authority, FAMHP, has approved the company’s clinical trial application for the first-in-human phase 1 study of its respiratory ...
SOUTH SAN FRANCISCO, Calif, January 10, 2020 – Meissa Vaccines (“Meissa”), a biotechnology company developing vaccines to prevent viral respiratory infections, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to MV-012-968, an investigational, live attenuated vaccine for protection against ...
Investigators have narrowed down his current whereabouts to a tropical climate with no extradition treaty. Respiratory Syncytial Virus RSV was once told to pick on somebody his own size—that’s how he got his start infecting infants. He’s little, he’s fierce, and he’s everywhere, which is why fellow Paramyxoviridae gang members ...
Influenza positivity decreased during week 9 2014, with 118 (26.3%) influenza positive specimens reported from the National Virus Reference Laboratory (NVRL): 74 influenza A(H3), 36 influenza A(H1)pdm09 and 8 influenza A (not subtyped). Respiratory syncytial virus (RSV) positivity reported from the NVRL during week 9 2014 was at low levels. ...